Krystal Biotech, Inc.
KRYS
Pozycja w akcjach
#2152
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Cena akcji
$320.50
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$9.49B
Zmiana (1 dzień)
1.24%
Zmiana (1 rok)
63.55%
Kraj
US
Handel Krystal Biotech, Inc. (KRYS)
Kategoria
Healthcare
Zyski dla Krystal Biotech, Inc. (KRYS)
Zyski w Jun 2026 TTM: $226.62M
Według najnowszych raportów finansowych Krystal Biotech, Inc., obecny zysk firmy wynosi $226.62M. W roku 2023 firma osiągnęła zysk w wysokości $12.90M, wzrost w porównaniu do zysku z roku 2022, który wynosił $-139.98M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Krystal Biotech, Inc. od 2016 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $226.62M | 137.66% |
| 2024 | $95.36M | 639.37% |
| 2023 | $12.90M | -109.21% |
| 2022 | $-139.98M | 101.20% |
| 2021 | $-69.57M | 116.28% |
| 2020 | $-32.17M | 68.52% |
| 2019 | $-19.09M | 75.30% |
| 2018 | $-10.89M | 37.49% |
| 2017 | $-7.92M | 588.70% |
| 2016 | $-1.15M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | 2,227.64% |
US
|
|
| $-3.09B | -1,462.19% |
US
|
|
| $-4.02B | -1,872.22% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 760.76% |
NL
|
